May 10, 2010 / 11:26 AM / 10 years ago

J&J shares have good upside: report

NEW YORK (Reuters) - Shares of Johnson & Johnson may come under pressure in the short term following the recent recall of its pediatric Tylenol and other products, but the company’s long-term prospects remain “sound,” Barron’s said in its May 10 edition.

Johnson & Johnson, which has had four recalls in the past year of over-the-counter medicines, most recently on April 30, has a diversified set of businesses, a strong balance sheet and a promising product pipeline, the financial newspaper said.

Citing Scott Glasser, co-portfolio manager of the large-cap-blend Legg Mason ClearBridge Appreciation Fund Barron’s wrote that the products affected by the most recent recall make up less than 1 percent of Johnson & Johnson’s expected 2010 revenue.

Johnson & Johnson were down 9 cents, or 0.1 percent, to close at $63.31 on Friday on the New York Stock Exchange.

Reporting by Phil Wahba

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below